Evidence mapping of clinical research on prevention and treatment of essential hypertension with Chinese patent medicines in recent six years.
10.19540/j.cnki.cjcmm.202206024.501
- Author:
Li-Jie QIAO
1
;
Bin LI
2
;
Yong-Xia WANG
2
;
Ming-Jun ZHU
2
Author Information
1. Henan University of Chinese Medicine Zhengzhou 450000, China.
2. the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
- Publication Type:Systematic Review
- Keywords:
Chinese patent medicine;
clinical research;
essential hypertension;
evidence map;
methodology
- MeSH:
Humans;
Asian People;
Drugs, Chinese Herbal/therapeutic use*;
Essential Hypertension/drug therapy*;
Medicine, Chinese Traditional;
Nonprescription Drugs/therapeutic use*;
Systematic Reviews as Topic;
Meta-Analysis as Topic
- From:
China Journal of Chinese Materia Medica
2022;47(19):5375-5382
- CountryChina
- Language:Chinese
-
Abstract:
In this study, the evidence mapping was employed to systematically analyze the clinical research literature and learn the distribution of evidence on the prevention and treatment of essential hypertension with Chinese patent medicines in recent six years. CNKI, Wanfang, VIP, SinoMed, PubMed, and Cochrane Library were searched for the relevant literature published from January 2016 to December 2021. The distribution characteristics of evidence were analyzed and presented in charts combined with words. A total of 263 studies were selected, including 238 intervention studies, 17 systematic reviews/Meta-analysis, and 8 observation studies. A total of 72 Chinese patent medicines were involved, among which Songling Xuemaikang Capsules had the highest frequency. In China, the attention to the treatment of essential hypertension with Chinese patent medicines was insufficient, as manifested by the declining number of published literature and the low quality of studies. There were cases of off-label use and medication without syndrome differentiation in clinical practice. Some outcome indicators failed to embody the characteristics of traditional Chinese medicine and there were cases ignoring the end-point outcome indicators. The overall quality of systematic reviews/Meta-analysis was low, and a variety of studies failed to draw valid conclusions. In the future, it is necessary to standardize the clinical medication and improve the quality of randomized controlled trial(RCT), so as to produce high-quality evidence-based medical evidence and provide strong support for the efficacy and safety of Chinese patent medicines in the prevention and treatment of essential hypertension.
